Claims
- 1. A composition comprising:
(a) at least one obesity control medication; and (b) at least one sterol absorption inhibitor or at least one 5α-stanol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof.
- 2. The composition according to claim 1, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (I):
- 3. The composition according to claim 2, wherein the sterol or 5α-stanol absorption inhibitor is represented by Formula (II) below:
- 4. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (III):
- 5. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (IV):
- 6. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (V):
- 7. The composition according to claim 1, where the at least one sterol absorption inhibitor is represented by Formula (VI):
- 8. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (VIIA) or (VIIB):
- 9. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (VIII):
- 10. The composition according to claim 1, wherein the at least one sterol absorption inhibitor is represented by Formula (IX):
- 11. The composition according to claim 1, wherein the at least one obesity medication is selected from the group consisting of noradrenergic agents, serotonergic agents, thermogenic agents and combinations thereof.
- 12. The composition according to claim 11, wherein the noradrenergic agent is selected from the group consisting of diethylpropion, mazindol, phenylpropanolamine, phentermine, phendimetrazine, phendamine tartrate, methamphetamine, phendimetrazine tartrate and combinations thereof.
- 13. The composition according to claim 11, wherein the serotonergic agent is selected from the group consisting of sibutramine, fenfluramine, dexfenfluramine, fluoxetine, fluvoxamine, paroxtine and combinations thereof.
- 14. The composition according to claim 11, wherein the thermogenic agent is selected from the group consisting of ephedrine, caffeine, theophylline, selective β3-adrenergic agonists and combinations thereof.
- 15. The composition according to claim 1, wherein the at least one obesity control medication is administered to a mammal in an amount ranging from about 1 to about 1000 milligrams of obesity medication per day.
- 16. The composition according to claim 1, wherein the at least one sterol or 5α-stanol absorption inhibitor is administered to a mammal in an amount ranging from about 0.1 to about 1000 milligrams of sterol or 5α-stanol absorption inhibitor per day.
- 17. The composition according to claim 1, wherein the at least one obesity control medication is an alpha-blocking agent.
- 18. The composition according to claim 1, wherein the at least one obesity control medication is a kainite or AMPA receptor antagonist.
- 19. The composition according to claim 1, wherein the at least one obesity control medication is a leptin-lipolysis stimulated receptor.
- 20. The composition according to claim 1, wherein the at least one obesity control medication is a phosphodiesterase enzyme inhibitor.
- 21. The composition according to claim 1, wherein the at least one obesity control medication is a compound having nucleotide sequences of the mahogany gene.
- 22. The composition according to claim 1, wherein the at least one obesity control medication is a fibroblast growth factor-10 polypeptide.
- 23. The composition according to claim 1, wherein the at least one obesity control medication is a monoamine oxidase inhibitor.
- 24. The composition according to claim 23, wherein the monoamine oxidase inhibitor is selected from the group consisting of befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, toloxatone, pirlindol, amiflamine, sercloremine, bazinaprine, lazabemide, milacemide, caroxazone and combinations thereof.
- 25. The composition according to claim 1, wherein the at least one obesity control medication is a compound for increasing lipid metabolism.
- 26. The composition according to claim 1, wherein the at least one obesity control medication is a lipase inhibitor.
- 27. A pharmaceutical composition for the treatment or prevention of obesity or lowering a concentration of a sterol or 5α-stanol in plasma of a mammal, comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically acceptable carrier.
- 28. A method of treating or preventing obesity or lowering a concentration of a sterol or 5α-stanol in plasma of a mammal, comprising the step of administering to a mammal in need of such treatment an effective amount of the composition of claim 1.
- 29. A therapeutic combination comprising:
(a) a first amount of at least one obesity control medication, and (b) a second amount of at least one sterol absorption inhibitor or 5α-stanol absorption inhibitor; wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of obesity or lowering a concentration of a sterol or 5α-stanol in plasma of a subject.
- 30. The therapeutic combination of claim 29, wherein the at least one sterol or 5α-stanol absorption inhibitor is represented by Formula (I):
- 31. The therapeutic combination according to claim 29, wherein the at least one obesity medication is administered concomitantly with the at least one sterol or 5α-stanol absorption inhibitor.
- 32. The therapeutic combination according to claim 29, wherein the at least one obesity medication and the at least one sterol or 5α-stanol absorption inhibitor are present in separate treatment compositions.
- 33. A method of treating or preventing obesity or lowering a concentration of a sterol in plasma of a subject, comprising the step of administering to a subject in need of such treatment an effective amount of the composition of claim 29.
- 34. A method of treating or preventing obesity comprising the step of administering to a subject in need of such treatment an effective amount of a composition comprising at least one sterol or 5α-stanol absorption inhibitor.
- 35. A method of treating or preventing obesity comprising the step of administering to a subject in need of such treatment an effective amount of a composition comprising at least one sterol absorption inhibitor represented by Formula (II) below:
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of priority from U.S. Provisional Patent Application Serial No. 60/323,840, filed Sep. 21, 2001, and is a continuation-in-part of U.S. patent application Ser. No. 10/166,942, filed Jun. 11, 2002, each incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60323840 |
Sep 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10166942 |
Jun 2002 |
US |
Child |
10247397 |
Sep 2002 |
US |